CRC patients with high ZEB1AS1 expression led to a poor prognosis and lower OS rate than those with low ZEB1AS1 expression, suggesting that ZEB1-AS1 is a promising biomarker in predicting clinical outcomes (50, 51). Here, ZEB1 is linked to colorectal carcinoma.